The Manufacturers Life Insurance Company grew its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 64.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,838 shares of the financial services provider’s stock after acquiring an additional 39,760 shares during the quarter. The Manufacturers Life Insurance Company owned 0.21% of iShares Biotechnology ETF worth $19,369,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Pension & Wealth Management Advisors Inc. acquired a new position in iShares Biotechnology ETF during the 2nd quarter valued at $28,000. Basepoint Wealth LLC acquired a new stake in iShares Biotechnology ETF in the 4th quarter worth $26,000. Cary Street Partners Financial LLC acquired a new stake in iShares Biotechnology ETF in the 4th quarter worth $29,000. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth about $25,000. Finally, Caitlin John LLC bought a new position in shares of iShares Biotechnology ETF during the 4th quarter worth about $34,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Up 0.1%
Shares of IBB opened at $202.93 on Friday. The company has a 50-day simple moving average of $199.42 and a 200-day simple moving average of $181.37. iShares Biotechnology ETF has a 52 week low of $138.79 and a 52 week high of $217.12.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
